Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline (2014)

Peer-Reviewed Study · Kamiński MF; Hassan C; Bisschops R; Pohl J; Pellisé M; Dekker E; Ignjatovic-Wilson A; Hoffman A; Longcroft-Wheaton G; Heresbach D; Dumonceau JM; East JE · March 17, 2014

Kamiński MF et al., 2014-03-17: European Society of Gastrointestinal Endoscopy clinical guideline recommending 0.1% methylene blue (or indigo carmine) pancolonic chromoendoscopy with targeted biopsies for neoplasia surveillance in long-standing colitis, a strong recommendation on high-quality evidence.

3 ESGE recommends the routine use of 0.1 % methylene blue or 0.1 % – 0.5 % indigo carmine pancolonic chromoendoscopy with targeted biopsies for neoplasia surveillance in patients with long-standing colitis.

Kamiński MF et al., 2014-03-17: European Society of Gastrointestinal Endoscopy clinical guideline recommending 0.1% methylene blue (or indigo carmine) pancolonic chromoendoscopy with targeted biopsies for neoplasia surveillance in long-standing colitis, a strong recommendation on high-quality evidence. Study type: society clinical practice guideline (GRADE). N: not applicable (evidence synthesis). Country: Europe (ESGE). Dose/route: 0.1% methylene blue, or 0.1%-0.5% indigo carmine, sprayed pancolonic. Comparator: standard-definition white-light endoscopy with non-targeted four-quadrant biopsies, which the guideline says can be abandoned under defined conditions. Funder: ESGE. Conflicts: individual author disclosures in the full guideline. This is the clearest official endorsement of a methylene blue detection technique in the record. Quote is a numbered recommendation (record field) transcribed from the guideline abstract. Study type: review.